NLRP3 and arrhythmogenic right ventricular cardiomyopathy: Together, these results suggest that pharmacological inhibition of NLRP3 may inactivate myeloid cell subpopulation associated with ARVC (Mye2) to solve to the inflammation and fibrosis of ARVC.